And so we welcome companies like Xaira to the space. We look forward to potentially collaborating with those companies, competing with those companies. What I can say is that we believe in tech bio. The primary bottleneck will be data. We’re seeing that where data exists, companies are making extraordinarily rapid progress with computational tools like machine learning and AI. And where data is sparse, it’s much, much more difficult. And so what we think Xaira will have to do is generate and aggregate high-quality data sets to make progress there. And the reality is that cells take time to grow, organoids take time to grow. And so, you know, we know that they’ve got an incredible team, and we look forward to seeing how they start to work in that space, continue to work to build the right data sets.
And certainly from our perspective, the more the merrier. We look forward to leading the space, and we’re so glad to see so many super competent companies joining us and others as we move towards what we see as an inevitable future. I think I’m going to do two more here. We’ve got a question from Hamida Alghazwi, who says, my daughter has Batten disease, CLN6, an ultra-rare genetic disease. Is Recursion willing to help labs who are interested in helping these kids, since we all know that pharmaceutical companies would not work for 35 patients, and how to establish that kind of relationship? Thanks, Hamida, for the question. My heart goes out to you, your daughter, your family, everybody else with Batten disease, and everybody else with a rare disease.
I think Recursion believes that by building maps of biology, by decoding biology, there will be a path forward to working across many of these diseases. We have a track record of working with patient groups. You can reach out to us via partnering at recursion.com and get connected to our patient advocacy team. There are scenarios where we have used our maps to work directly with patient advocates to try and advance programs forward. And ultimately, we do believe that companies like Recursion and others, as tech bio comes into the space, even if we don’t have a clear hypothesis today around CLN6, and I don’t know, I don’t have the map pulled up right now, but even if we don’t have a clear hypothesis around CLN6 today or other areas of Batten disease, these kinds of approaches, these scaled approaches, are going to be really, really exciting in the medium to long term.
And I know that’s no consolation to you and your daughter today, but my hope is that in 5 to 10 years it’s not going to be hard to see a biopharma company working across diseases that have 35 patients or maybe even less. Thank you so much for your question. And again, reach out to partnering at recursion.com. All right. And finally, we’ve got a final question here. There’s a question about my beard, which I’m going to not answer and I will move on to a question from, but thank you to Alex at Bank of America and for the question about my beard. I’ll go to Amir Shahin, who asked, what’s on the wish list, the next big pieces of the puzzle that we need to get put in place in the wider community over a five-year horizon and a 15-year horizon in order for us to progress as fast as possible and using state-of-the-art computation for drug discovery.
Amir, I think it really comes down to the data sets. And we believe that, ultimately, to fully understand biology, people are going to need to build out really deep, broad data sets. And you’re not going to need to build out the 100s of these you’re going to need to build out a dozen or two dozen technologies, maybe its Phenomics, Proteomics, Metabolomics, Lipidomics, Transcriptomics, Euvolemic add some scale, alongside Predictive ADME datasets, Tox Datasets, alongside Automated Synthesis and on the large molecule side moving in the direction of other modalities, RNAi therapies, Antibody Therapies, other kind of Gene Therapies I think there will be a dozen or two dozen scaled technologies. And the company who can bring together the highest number of those over the next five to 10 years in a disciplined and robust way is going to start to be able to pull out compounding efficiencies.
So that even if you only make each step of drug discovery and development 5%, 20% better than it was before and you start to layering this technologies together as I think Recursion is really doing at least my belief more and better than any other TechBio start up in the space. You are going to start pulling together these compounding efficiencies, and that’s going to create this flywheel of momentum and opportunity. And of course, we’ve got programs that are going to be reading out from our first-generation platform the coming quarters. We’re excited then for our second-generation molecule to start reading out after that, and we hope a third, a fourth, a fifth generation and at each stage will be able to demonstrate higher scale, lower cost, more rapid translation of these programs and ultimately, the biggest lever will be probability of success.
As you all know, 90% of drugs fail in the clinics today from start to getting to the market. And if we can get as an industry to 80% failure and then 70% failure and then 60% failure we’re going to dramatically improve the access to medicines and dramatically reduce the price of medicines over the coming decades. And we want to make sure that we are doing an experiment to ask and answer the kinds of tools that we’re building can help lead out with that kind of vision. So watch for us to continue to build the vertical with small molecules and then as we make a lot of progress in that space, we start to demonstrate successes in that space. You can see Recursion thinking about moving into complementary modalities as well so we can go after a broader range of diseases, both with our internal pipeline and with our biopharma partners.
All right. Thanks, everybody. It’s been fantastic to connect with you all for these 35 minutes here at our Q1 2024 earnings. Please follow us on social. Please post questions at our future learnings calls. And please engage with us at conferences and in other ways, we’re so excited to be having this conversation with all of you and to be leading the TechBio field as we move Biotech into TechBio. Thanks, everybody. And have a fantastic evening. Bye-bye.
End of Q&A: